<DOC>
	<DOCNO>NCT02085265</DOCNO>
	<brief_summary>The purpose project conduct proof concept study patient probable Alzheimer 's Disease mild moderate hypertension , order determine less global brain atrophy one year , measure ventricular enlargement primary outcome measure , patient randomize treatment angiotensin receptor blocker compare Angiotensin Converting Enzyme inhibitor ( ACEI ) .</brief_summary>
	<brief_title>Telmisartan vs. Perindopril Hypertensive Mild-Moderate Alzheimer 's Disease Patients</brief_title>
	<detailed_description>This study use simple validated measure brain atrophy surrogate marker repurposing effort could recast antihypertensive medication cognitive enhancer /neuroprotective agent possibly drug choice Alzheimer patient patient risk AD . If proof concept result positive , large study would warrant potential practice-changing impact .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Perindopril</mesh_term>
	<criteria>1 . Previously establish clinical diagnosis probable AD dementia new McKhann criteria63 2 . Previous brain MRI CT scan within last 2 year rule exclusionary pathology , cortical stroke , tumour , subdural hematoma , malformation , etc . 3 . Age 55 year old 4 . Established diagnosis hypertension least one hypertensive medication 5 . Standardized Mini Mental State Examination ( SMMSE ) score 1627 screen visit 6 . Sufficient hear vision participate test per investigator 's judgement 7 . Sufficient fluency English able complete language cognitive test 8 . At least 8 year education 9 . A study partner opinion study investigator regular interaction patient , present clinic visit , provide collateral history assist compliance study procedures 10 . Stable dose cholinesterase inhibitor ( ChEI ) and/or memantine least 3 month prior randomization visit 11 . HbA1C &lt; 8.5 % . Patients stable type II diabetes eligible study follow condition meet : severe hypoglycemic event require third party intervention ( e.g . emergency department visit ) within 6 month , medication therapy stable least 3 month limited oral antidiabetic agent and/or basal insulin therapy per day 12 . Patients medication vascular risk factor ( e.g. , hypertension , cholesterol ) must stable dose ≥3 month prior randomization . Exclusion criteria 1 . Intolerance , contraindication , study medication 2 . Familial autosomal dominant form Alzheimer 's disease 3 . Creatinine clearance less equal 30ml/min 4 . Serum potassium &gt; 5.5 mEq/L 5 . ALT &gt; upper limit normal ( ULN ) 6 . History angioedema 7 . Comorbid acute chronic condition ( include type I diabetes mellitus , stroke , neurological condition Parkinson 's disease , psychiatric disorder , severe unstable medical condition ) could confound assessment would , judgment investigator , make subject inappropriate entry study 8 . Severe periventricular white matter disease ( Fazekas score 3 ) , cortical infarction , lacunar infarct &lt; 1.5 cm diameter basal ganglia thalamus &gt; 2 lacunar infarct ( &lt; 1.5cm diameter ) elsewhere screen MRI 9 . Inability perform study procedure , include claustrophobia contraindication MRI 10 . Currently take angiotensin receptor blocker within 12 month randomization visit 11 . Resides nurse home ( participant reside retirement home may include study partner meet inclusion criterion # 9 ) 12 . Current major depression clinical history score great 18 Cornell Scale Depression Dementia 13 . Documented potential cardiac source brain infarction mechanical valve type atrial fibrillation 14 . Regular use psychotropic medication , shortacting benzodiazepine sleep nonanticholinergic antidepressant ( stable dose 3 month time randomization ) ; exception ( e.g . antipsychotic medication ) may permit casebycase basis , upon consultation Dr. Krista Lanctôt</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Perindopril</keyword>
	<keyword>Telmisartan</keyword>
	<keyword>Brain atrophy</keyword>
</DOC>